Amitriptyline
Increased risk of postural hypotension
Amoxapine
Increased risk of postural hypotension
Cisapride
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Trifluoperazine is contraindicated.
Clomipramine
Increased risk of postural hypotension
Dothiepin
Increased risk of postural hypotension
Doxepin
Adverse Effect: Increased risk of postural hypotension
Erithrityl Tetranitrate
Increased risk of postural hypotension
Glyceryl Trinitrate
Increased risk of postural hypotension
Imipramine
Increased risk of postural hypotension
Isosorbide 5 Mononitrate
Increased risk of postural hypotension
Isosorbide Dinitrate
Increased risk of postural hypotension
Levodopa
Adverse Effect: Loss of levodopa efficacy Clinical Management: Concurrent use of trifluoperazine and levodopa should be avoided. If concomitant use is necessary, monitor the patient for loss of levodopa therapeutic efficacy.
Lithium
Adverse Effect: weakness, dyskinesias, increased extrapyramidal symptoms, encephalopathy, and brain damage Clinical Management: Monitor patients closely for any signs of toxicity or extrapyramidal symptoms, especially if high doses of antipsychotic drugs and lithium are used.
Nitroxazapine
Increased risk of postural hypotension
Nortriptyline
Increased risk of postural hypotension
Pentaerythritol Tetranitrate
Increased risk of postural hypotension
Pethidine
Adverse Effect: Increase in central nervous system and respiratory depression Clinical Management: Monitor patients for signs of respiratory depression, CNS depression, and hypotension. A dosage reduction or discontinuation of one or both drugs may be necessary.
Phenytoin
Adverse Effect: Increased or decreased phenytoin levels and possibly reduced Trifluoperazine levels Clinical Management: Consider monitoring phenytoin levels when a Trifluoperazine is added or discontinued from therapy; dosage adjustments may be needed in some cases. The patient should also be observed for any signs of phenytoin toxicity (ataxia, nystagmus, tremor, hyperreflexia), particularly in case of adjustments to the Trifluoperazine dosage. Observe patients for Trifluoperazine efficacy.
Pimozide
Adverse Effect: Increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Pimozide is contraindicated in individuals with congenital QT syndrome, patients with a history of cardiac arrhythmias, or patients taking other drugs which may prolong the QT interval.
Procyclidine
Adverse Effect: decreased Trifluoperazine serum concentrations, decreased Trifluoperazine effectiveness, enhanced anticholinergic effects (ileus, hyperpyrexia, sedation, dry mouth) Clinical Management: Anticholinergics (benztropine, orphenadrine, procyclidine, trihexyphenidyl) should not be used routinely with Trifluoperazine derivatives as prophylaxis against possible extrapyramidal symptoms; use should be reserved for situations where EPS occur and lowering of the antipsychotic dosage is not possible.
Sotalol
Adverse Effect: Increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent administration of sotalol and a Trifluoperazine is not recommended.
Sparfloxacin
Adverse Effect: prolongation of the QTc interval and/or torsades de pointes Clinical Management: Sparfloxacin is contraindicated in individuals with known QTc prolongation or in patients being treated concurrently with drugs that are known to increase the QTc interval and/or cause torsades de pointes.
Tramadol
Adverse Effect: Increased risk of seizures Clinical Management: Caution should be used if tramadol is to be administered to patients receiving Trifluoperazine therapy. If possible, avoid this combination
Trazadone
Adverse Effect: Hypotension Clinical Management: Monitor blood pressure, particularly in patients who might be sensitive to this effect. Advise patient to rise slowly from lying or sitting position.
Trihexiphenidyl
Adverse Effect: decreased Trifluoperazine serum concentrations, decreased Trifluoperazine effectiveness, and enhanced anticholinergic effects (ileus, hyperpyrexia, sedation, dry mouth) Clinical Management: Anticholinergics (benztropine, orphenadrine, procyclidine, trihexyphenidyl) should not be used routinely with Trifluoperazine derivatives as prophylaxis against possible extrapyramidal symptoms.
Trimipramine
Increased risk of postural hypotension |